Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses
- 1 March 2012
- journal article
- clinical trial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (5), 1426-1434
- https://doi.org/10.1158/1078-0432.ccr-11-1221
Abstract
Purpose: To show that the immunomodulatory drug lenalidomide can be used in patients with relapsed multiple myeloma to augment vaccine responses. Experimental Design: Early phase clinical trial of patients with multiple myeloma who received at least one prior therapy. Patients were treated with single-agent lenalidomide and randomized to receive two vaccinations with pneumococcal 7-valent conjugate vaccine (PCV) on different schedules. Cohort A received the first PCV vaccination prior to the initiation of lenalidomide and the second vaccination while on lenalidomide. Cohort B received both vaccinations while on lenalidomide. Results: PCV-specific humoral and cellular responses were greater in cohort B than A and were more pronounced in the bone marrow than the blood, suggesting that maximal vaccine efficacy was achieved when both vaccines were administered concomitantly with lenalidomide. Patients with a clinical myeloma response showed evidence of a tumor-specific immune response with increases in myeloma-specific IFN-γ+ T cells and reductions in Th-17 cells. Conclusions: This is the first clinical evidence showing that lenalidomide augments vaccine responses and endogenous antitumor immunity in patients and as such may serve as an adjuvant for cancer and possibly infectious vaccines. Clin Cancer Res; 18(5); 1426–34. ©2012 AACR.Keywords
Other Versions
This publication has 37 references indexed in Scilit:
- Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myelomaBlood, 2010
- Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysisLeukemia & Lymphoma, 2010
- Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different waysMolecular Cancer, 2010
- Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapyBlood, 2009
- Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal CancerJournal of Clinical Oncology, 2009
- T‐lymphocyte interaction with stromal, bone and hematopoietic cells in the bone marrowImmunology & Cell Biology, 2008
- Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primatesJCI Insight, 2008
- Human Epidermal Growth Factor Receptor 2 Status Correlates With Lymph Node Involvement in Patients With Estrogen Receptor (ER) –Negative, but With Grade in Those With ER-Positive Early-Stage Breast Cancer Suitable for Cytotoxic ChemotherapyJournal of Clinical Oncology, 2007
- Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implicationsBlood, 2006
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006